Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0090
0.00 (0.00%)
Sep 11, 2026, 9:59 AM AEST
Radiopharm Theranostics Revenue
In the fiscal year ending June 30, 2026, Radiopharm Theranostics had annual revenue of 13.50M AUD with 7.91% growth. Radiopharm Theranostics had revenue of 7.30M in the half year ending June 30, 2026.
Revenue
13.50M
Revenue Growth
+7.91%
P/S Ratio
2.89
Revenue / Employee
964.45K
Employees
14
Market Cap
39.04M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 13.50M | 990.09K | 7.91% |
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 46.28M |
| Botanix Pharmaceuticals | 33.80M |
| Neurizon Therapeutics | 17.59M |
| Argenica Therapeutics | 5.48M |
| Amplia Therapeutics | 4.79M |
| Prescient Therapeutics | 3.45M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
Radiopharm Theranostics News
- 1 day ago - Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer - Nasdaq
- 1 day ago - Radiopharm announces data from imaging trial of RAD 301 - TheFly
- 1 day ago - Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 15 days ago - Radiopharm Doses First Patient In Second Cohort Of Phase 1/2a RV-01 Trial - Nasdaq
- 15 days ago - Radiopharm doses first patient in second cohort of RV-01 trial - TheFly
- 15 days ago - Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors - GlobeNewsWire
- 21 days ago - Radiopharm Advances RAD202 Phase 1 Trial To Higher 180mCi Dose Level - Nasdaq
- 21 days ago - Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial - GlobeNewsWire